跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 15 条关于
“Orpathys”
全部
15
临床试验
1
药物
1
机构
0
资讯
13
去年
HUTCHMED's ORPATHYS and TAGRISSO Combination Receives Priority Review in China for Lung Cancer
去年
TAGRISSO and ORPATHYS Combination Shows Promise in MET-Driven EGFR-Mutated NSCLC
去年
China Approves ORPATHYS-TAGRISSO Combination for EGFR-Mutated Lung Cancer with MET Amplification
4年前
China NMPA Accepts NDA for ORPATHYS® and TAGRISSO® Combination in NSCLC with MET Amplification
6小时前
Hutchmed Reports Positive Phase III SANOVO Trial Results in Lung Cancer
去年
AbbVie's Telisotuzumab Vedotin Shows Promise in c-Met Overexpressing NSCLC
4年前
HUTCHMED Announces Savolitinib sNDA Accepted in China for NSCLC Treatment
9个月前
HUTCHMED Secures Continued NRDL Coverage for Three Cancer Drugs and Gains Commercial Insurance Access for Tazemetostat in China
2年前
Lenvatinib and Pembrolizumab Combination Shows Promise in Non-Clear Cell Renal Cell Carcinoma Subtypes
去年
Savolitinib Plus TAGRISSO® Shows 56% Response Rate in MET-High Lung Cancer, HUTCHMED Reports
第 1 页,共 2 页
上一页
下一页